Impact BioMedical Reports Financial Challenges with $1.47M Net Loss in Latest Quarter

Impact BioMedical, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated total revenue of $18,000 for the three months ended September 30, 2025, and $25,000 for the nine months ended September 30, 2025, marking a stark contrast to the previous fiscal period when it reported no revenue. The company’s operating loss for the quarter was $948,000, compared to a loss of $1,127,000 in the same quarter of the previous year. For the nine-month period, the operating loss increased to $3,112,000 from $2,522,000 year-over-year. The net loss attributable to common stockholders was $1,470,000 for the quarter and $17,083,000 for the nine months, a significant decline from the net income of $4,247,000 and $2,400,000 reported in the same periods of 2024.

The company’s financial position has deteriorated, with total assets decreasing to $18.2 million as of September 30, 2025, down from $20.3 million at the end of 2024. Current liabilities surged to $23.8 million, primarily due to a substantial increase in the note payable to a related party, which rose to $22.9 million from $8.9 million. This increase reflects the company's ongoing financial struggles and reliance on debt financing. The accumulated deficit also widened significantly to $54.8 million, compared to $37.7 million at the end of the previous fiscal year.

Strategically, Impact BioMedical has made notable moves, including the acquisition of assets from DSS PureAir for $1.15 million, which included intellectual property related to air purification technology. This acquisition, completed in February 2025, is part of the company's efforts to expand its product offerings. The company has also initiated a focus on monetizing its intellectual properties and controlling operating costs to improve its financial outlook. However, the company has not reported significant customer growth or product adoption metrics, indicating challenges in market penetration.

Operationally, the company has seen a 97% increase in sales, general, and administrative compensation costs, attributed to increased headcount and bonus accruals. Conversely, research and development expenses decreased by 37% for the quarter, reflecting a strategic pause in spending on new technologies. The company’s cash position has also weakened, with cash and cash equivalents dropping to $12,000 from nearly $2 million at the end of 2024. The management has expressed concerns about the company's ability to continue as a going concern, emphasizing the need for strategic actions to stabilize its financial situation.

Looking ahead, Impact BioMedical's management is focused on executing its business plan post-IPO, which includes potential mergers and acquisitions. The company aims to leverage its unique technologies in biopharmaceuticals and wellness products while navigating the challenges posed by its current financial state. The outlook remains uncertain, with management acknowledging the risks associated with its operational and financial strategies.